OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

AstraZeneca733 enrolled

Overview

OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent. In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.

Study Type

OBSERVATIONAL

Enrollment

733

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects suffering from diabetes type 2, * treated or untreated, * insulin dependent or not insulin dependent Able to read and send SMS (if SMS applicable) Exclusion Criteria: * Type 1 diabetes Pregnancy diabetes * Hospitalization at the moment of enrollment in the study

Locations (20)

Research Site

Blagoevgrad, Bulgaria

Research Site

Pleven, Bulgaria

Research Site

Plovdiv, Bulgaria

Outcomes

Primary Outcomes

Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1

To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure, expressed as the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1

Time frame: after 12 months of follow-up

Secondary Outcomes

Quality of patient care improvement, in particular the control of diabetes, lipids and blood pressure

To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure

Time frame: after 12 months of follow-up versus baseline

Markers of preventive screening

To follow up evolution markers of preventive screening; retinopathy, neuropathy, dietary counseling, smoking habits, BMI, waist circumference, physical activity

Time frame: after 12 months of follow-up versus baseline

The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines

To investigate the LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines

Time frame: after 12 months of follow-up versus baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.